Low‐dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma

Abstract

Baumann, T., Delgado, J., Santacruz, R., MartinezTrillos, A., Royo, C., Navarro, A., Pinyol, M., Rozman, M., Pereira, A., Villamor, N., Aymerich, M., Lopez, C., Carrio, A. & Montserrat, E. (2014) Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica, 99, 1599–1604. Burger, J.A., Tedeschi, A., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N.L., Li, J., Simpson, D., Grosicki, S., Devereux, S., McCarthy, H., Coutre, S., Quach, H., Gaidano, G., Maslyak, Z., Stevens, D.A., Janssens, A., Offner, F., Mayer, J., O’Dwyer, M., Hellmann, A., Schuh, A., Siddiqi, T., Polliack, A., Tam, C.S., Suri, D., Cheng, M., Clow, F., Styles, L., James, D.F. & Kipps, T.J. (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine, 373, 2425–2437. Byrd, J.C., Brown, J.R., O’Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Devereux, S., Barr, P.M., Furman, R.R., Kipps, T.J., Cymbalista, F., Pocock, C., Thornton, P., Caligaris-Cappio, F., Robak, T., Delgado, J., Schuster, S.J., Montillo, M., Schuh, A., de Vos, S., Gill, D., Bloor, A., Dearden, C., Moreno, C., Jones, J.J., Chu, A.D., Fardis, M., McGreivy, J., Clow, F., James, D.F. & Hillmen, P. (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine, 371, 213–223. Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R.S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N.L., Dilhuydy, M.S., Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Mato, A., Pavlovsky, M.A., Karlsson, C., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. & Hallek, M. (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. The Lancet. Oncology, 17, 200–211. Eichhorst, B., Fink, A.M., Busch, R., Kovacs, G., Maurer, C., Lange, E., K€ oppler, H., Kiehl, M.G., Pl€ oger, C., Gregor, M., Plesner, T., Trneny, M., Fischer, K., D€ ohner, H., Kneba, M., Wendtner, C.M., Klapper, W., Kreuzer, K.A., Stilgenbauer, S., B€ ottcher, S. & Hallek, M. (2014) Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (56th ASH Annual Meeting Abstracts and Meeting Program), 124, 19. Goede, V., Cramer, P., Busch, R., Bergmann, M., Stauch, M., Hopfinger, G., Stilgenbauer, S., Dohner, H., Westermann, A., Wendtner, C.M., Eichhorst, B. & Hallek, M. (2014) Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica, 99, 1095–1100. Gordon, M.J., Churnetski, M., Alqahtani, H., Rivera, X., Kittai, A., Amrock, S.M., James, S., Hoff, S., Manda, S., Spurgeon, S.E., Choi, M., Cohen, J.B., Persky, D. & Danilov, A.V. (2018) Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer, 124, 3192–3200. Smelick, G.S., Heffron, T.P., Chu, L., Dean, B., West, D.A., DuVall, S.L., Lum, B.L., Budha, N., Holden, S.N., Benet, L.Z., Frymoyer, A., Dresser, M.J. & Ware, J.A. (2013) Prevalence of acidreducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Molecular Pharmacology, 10, 4055–4062.